# US 10,117,893 B2 · Therapeutic gas for the treatment of mitochondrial disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,893 B2
- Document ID: US10117893B2
- Status: Granted
- Kind: B2
- Application number: 13/504,821
- Filed: 2010-10-27
- Published: 2012-08-23
- Granted: 2018-11-06
- Earliest claimed: 2009-10-27
- Assignees: Bernd-Michael Loeffler
- Applicants: Bernd-Michael Loeffler
- Inventors: Bernd-Michael Loeffler
- Web page: https://patentgrep.com/patent/US10117893B2

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61M 16/10: Preparation of respiratory gases or vapours
- A61M 16/101: {using an oxygen concentrator}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61M 2016/1025: {the O2 concentration}
- A61M 2202/0208: Oxygen
- A61M 2230/205: partial oxygen pressure (P-O2)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The use of gaseous oxygen for the production of a therapeutic gas for inhalation by a patient who has been identified as a person with a mitochondrial disorder or a coenzyme Q10 deficiency, for the treatment of mitochondrial disorders or Q10 deficiencies is disclosed. For the first time a non-invasive method is disclosed, upon what the body's own level of Q10 can be raised significantly without further interventions.

## Claims

### Claim 1

A method for the treatment of mitochondrial disorders or coenzyme Q10 deficiencies, the method comprising:
a) identifying a person with a mitochondrial disorder or a coenzyme Q10 deficiency; and
b) administering to the person via inhalation a therapeutic gas comprising gaseous oxygen in the form of an intermittent hypoxia-hyperoxia therapy, wherein sessions of inhalation of hypoxygenic and hyperoxygenic gases alternate and wherein the concentration of oxygen in the therapeutic gas is from about 15 Vol-% to about 9 Vol-% for a hypoxia session;
wherein inhalation of the gas is performed in at least two time sessions, one of the time sessions being a hypoxia session of 6 minutes in which the concentration of oxygen in the therapeutic gas is 12 Vol-% and another of the time sessions being a hyperoxia session of 3 minutes in which the concentration of the oxygen in the therapeutic gas is 44 Vol-% and wherein the inhalation of the therapeutic gas results in an increase of coenzyme Q10 to a therapeutic range of 2.5 mg/l in plasma of the person.

### Claim 2

A method for the treatment of mitochondrial disorders or coenzyme Q10 deficiencies, the method comprising:
a) identifying a person with a mitochondrial disorder or a coenzyme Q10 deficiency; and
b) administering to the person via inhalation a therapeutic gas comprising gaseous oxygen in the form of an intermittent hypoxia-hyperoxia therapy, wherein sessions of inhalation of hypoxygenic and hyperoxygenic gases alternate and wherein the concentration of oxygen in the therapeutic gas is from about 15 Vol-% to about 9 Vol-% for a hypoxia session;
wherein inhalation of the gas is performed in at least four cycles, each cycle comprising a hypoxia session of 6 minutes in which the concentration of oxygen in the therapeutic gas is 12 Vol-% followed by a hyperoxia session of 3 minutes in which the concentration of the oxygen in the therapeutic gas is 44 Vol-% and wherein the inhalation of the therapeutic gas results in an increase of coenzyme Q10 to a therapeutic range of 2.5 m/1l in plasma of the person.

### Claim 3

A method for the treatment of mitochondrial disorders or coenzyme Q10 deficiencies, the method comprising:
a) identifying a person with a mitochondrial disorder or a coenzyme Q10 deficiency; and
b) administering to the person via inhalation a therapeutic gas comprising gaseous oxygen in the form of an intermittent hypoxia-hyperoxia therapy, wherein sessions of inhalation of hypoxygenic and hyperoxygenic gases alternate and wherein the concentration of oxygen in the therapeutic gas is from about 15 Vol-% to about 9 Vol-% for a hypoxia session;
wherein inhalation of the gas is performed in at least two time sessions, one of the time sessions being a hypoxia session of 1 minute in which the concentration of oxygen in the therapeutic gas is 13 Vol-% and another of the time sessions being a hyperoxia session of 9 minutes in which the concentration of the oxygen in the therapeutic gas is 38 Vol-% and wherein the inhalation of the therapeutic gas results in an increase of coenzyme Q10 to a therapeutic range of 2.5 m/1l in plasma of the person.

### Claim 4

A method for the treatment of mitochondrial disorders or coenzyme Q10 deficiencies, the method comprising:
a) identifying a person with a mitochondrial disorder or a coenzyme Q10 deficiency; and
b) administering to the person via inhalation a therapeutic gas comprising gaseous oxygen in the form of an intermittent hypoxia-hyperoxia therapy, wherein sessions of inhalation of hypoxygenic and hyperoxygenic gases alternate and wherein the concentration of oxygen in the therapeutic gas is from about 15 Vol-% to about 9 Vol-% for a hypoxia session;
wherein inhalation of the gas is performed in at least six cycles, each cycle comprising a hypoxia session of 1 minute in which the concentration of oxygen in the therapeutic gas is 13 Vol-% followed by a hyperoxia session of 9 minutes in which the concentration of the oxygen in the therapeutic gas is 38 Vol-% and wherein the inhalation of the therapeutic gas results in an increase of coenzyme Q10 to a therapeutic range of 2.5 mg/l in plasma of the person.

### Claim 5

A method for the treatment of mitochondrial disorders or coenzyme Q10 deficiencies, the method comprising:
a) identifying a person with a mitochondrial disorder or a coenzyme Q10 deficiency; and
b) administering to the person via inhalation a therapeutic gas comprising gaseous oxygen in the form of an intermittent hypoxia-hyperoxia therapy, wherein sessions of inhalation of hypoxygenic and hyperoxygenic gases alternate and wherein the concentration of oxygen in the therapeutic gas is from about 15 Vol-% to about 9 Vol-% for a hypoxia session;
wherein the concentration of the oxygen in the therapeutic gas is about 55 Vol-% for a hyperoxia session and wherein the inhalation of the therapeutic gas results in an increase of coenzyme Q10 to a therapeutic range of 2.5 mg/l in plasma of the person.